Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Allakos Inc. (ALLK)

Pharmaceutical Preparations

https://www.allakos.com

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

825 INDUSTRIAL ROAD, SUITE 500
SAN CARLOS, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/19/2018

Market Cap

56,846,678

Shares Outstanding

87,480,000

Weighted SO

87,476,338

Total Employees

N/A

Upcoming Earnings

08/14/2024

Beta

0.8650

Last Div

0.0000

Range

0.6348-3.41

Chg

-0.0177

Avg Vol

593264

Mkt Cap

56846678

Exch

NASDAQ

Country

US

Phone

650 597 5002

DCF Diff

0.3509

DCF

0.2877

Div Yield

0.0000

P/S

5.2851

EV Multiple

-0.3840

P/FV

0.6752

Div Yield %

0.0000

P/E

-0.2753

PEG

-0.0048

Payout

0.0000

Current Ratio

3.5654

Quick Ratio

3.5654

Cash Ratio

0.7385

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

1167.1166

CCC

-1167.1166

Gross Margin

0.5313

Op Margin

-17.4366

Pretax Margin

-19.1520

Net Margin

-19.1520

Eff Tax Rate

-0.0252

ROA

-1.3166

ROE

-1.4260

ROCE

-1.5554

NI/EBT

1.0000

EBT/EBIT

1.0984

EBIT/Rev

-17.4366

Debt Ratio

0.2540

D/E

0.4730

LT Debt/Cap

0.3034

Total Debt/Cap

0.3211

Int Coverage

-70.9871

CF/Debt

-2.5975

Equity Multi

1.8626

Rec Turnover

0.0000

Pay Turnover

0.3127

Inv Turnover

0.0000

FA Turnover

0.4011

Asset Turnover

0.0687

OCF/Share

-1.1643

FCF/Share

-1.1657

Cash/Share

1.3889

OCF/Sales

-9.5955

FCF/OCF

1.0012

CF Coverage

-2.5975

ST Coverage

-32.7128

CapEx Coverage

-867.3025

Div&CapEx Cov

-867.3025

P/BV

0.6752

P/B

0.6752

P/S

5.2851

P/E

-0.2753

P/FCF

-0.5502

P/OCF

-0.5495

P/CF

-0.5495

PEG

-0.0048

P/S

5.2851

EV Multiple

-0.3840

P/FV

0.6752

DPS

0.0000

Latest Headlines (EST)

Benzinga Jan 16, 09:49 Dow Dips 200 Points; Goldman Sachs Earnings Top Views Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Investing.com Dec 23, 11:00 Street Calls of the Week: Pepsi may fizzle out Benzinga Dec 18, 12:34 Allakos Analyst Turns Bullish, Sees 'Significant Upside' If Study Results Are Positive

Revenue Product Segmentation